Precursor to Blood Cancer Is'Tricky to Diagnose,' Study Shows
WEDNESDAY, Aug. 9, 2023 -- New research shows hard-to-diagnose blood disorders called myelodysplastic syndromes/neoplasms (MDS) are often misdiagnosed and a second opinion may be needed.
The difficulty of diagnosis and frequent misdiagnosis puts... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 9, 2023 Category: General Medicine Source Type: news
International Prognostic Scoring System-Molecular Changes Clinical Management
FRIDAY, June 16, 2023 -- Implementing the International Prognostic Scoring System-Molecular (IPSS-M) in clinical practice could impact clinical management for nearly half of patients with myelodysplastic syndromes (MDS), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 16, 2023 Category: Pharmaceuticals Source Type: news
Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS
(MedPage Today) -- CHICAGO -- Patients with transfusion-dependent, low-risk myelodysplastic syndromes (MDS) needed significantly fewer transfusions when treated with luspatercept (Reblozyl) for anemia compared with the current standard of care... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - May 25, 2023 Category: Urology & Nephrology Source Type: news
MRI-Based AI Can Distinguish Aplastic Anemia From MDS
MONDAY, April 24, 2023 -- A magnetic resonance imaging (MRI)-based machine learning method can distinguish aplastic anemia (AA) from myelodysplastic syndromes (MDS), according to a study published online March 6 in Clinical Radiology.
P. Xiang,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2023 Category: Pharmaceuticals Source Type: news
FDA and NIH/NCI Center for Cancer Research: Advancing Drug Development in Myelodysplastic Syndromes - 05/16/2023
FDA and NIH/NCI Center for Cancer Research: Advancing Drug Development in Myelodysplastic Syndromes. Virtual 2-day free public workshop. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 20, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Processed Red Meat Intake Linked to Increased Incidence of Blood Cancers
FRIDAY, March 24, 2023 -- Processed red meat intake is associated with an increased incidence of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in a Japanese population, according to a study published online March 7 in Environmental... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2023 Category: Pharmaceuticals Source Type: news
Allogeneic Stem Cell Transplant Feasible for Leukemia in Elderly Patients
TUESDAY, Feb. 21, 2023 -- In elderly adults aged 60 years and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), allogeneic hematopoietic stem cell transplant (HSCT) can be performed with acceptable overall survival and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2023 Category: Pharmaceuticals Source Type: news
What Laboratory Tests Are Consistent with Transient Erythroblastopenia of Childhood?
Discussion
Transient erythroblastopenia of childhood (TEC) is an “…anemia with a hemoglobin level at least 2 [standard deviations] below normal and a low reticulocyte count in relationship to the anemia in the absence of evidence of alternative causes of anemia.” A bone marrow aspirate shows decreased or absent erythroid precursor cells if obtained. The etiology is not well understood but may have a stimulating cause such as a viral infection, an immune-related and/or genetic cause. Parvovirus causing bone marrow suppression has been implicated and there are cases of affected siblings.
TEC is most common ...
Source: PediatricEducation.org - February 6, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Inflammatory VEXAS Syndrome May Not Be So Uncommon
(MedPage Today) -- VEXAS syndrome, a newly discovered inflammatory disease that has rheumatologic and hematologic features caused by mutations in the UBA1 gene, may be as common as Behcet's disease or myelodysplastic syndrome (MDS), researchers... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - January 24, 2023 Category: Rheumatology Source Type: news
2022 ICC Recategorization Facilitates Risk Stratification of Myelodysplastic Syndrome
THURSDAY, Jan. 19, 2023 -- Clinical characteristics, outcomes, and genetic features vary among different myelodysplastic syndrome (MDS) subtypes categorized using the 2022 International Consensus Classification (ICC), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2023 Category: Pharmaceuticals Source Type: news
Five-Year Relative Survival 59.6 Percent in Lower-Risk Myelodysplastic Syndromes
WEDNESDAY, Nov. 23, 2022 -- About 40 percent of patients with lower-risk myelodysplastic syndromes (LR-MDS) die of MDS within five years, according to a study published online Nov. 6 in the British Journal of Haematology.
Krzysztof M ądry, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2022 Category: Pharmaceuticals Source Type: news
Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS
(MedPage Today) -- The investigational anti-CD47 monoclonal antibody magrolimab combined with azacitidine showed promising efficacy and was well tolerated in patients with untreated higher-risk myelodysplastic syndromes (MDS), according to a phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 29, 2022 Category: Hematology Source Type: news
Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes
(MedPage Today) -- Low-dose hypomethylating agents (HMAs) was associated with favorable outcomes in previously untreated lower-risk myelodysplastic syndromes (MDS), according to a long-term analysis of a randomized phase II study.
With a follow... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 23, 2022 Category: Hematology Source Type: news
Camp Lejeune Veterans Win Justice
On Wednesday, Aug. 10, President Joe Biden signed the comprehensive Honoring Our PACT Act of 2022 into law, allowing military veterans and families harmed by contaminated water at Marine Corps Base Camp Lejeune to file lawsuits against the federal government.
The Camp Lejeune Justice Act of 2022, which focuses on four decades of water contamination, is just one part of the much broader PACT Act, which expands access to health care and disability benefits for veterans harmed by toxic exposures around the world.
Biden lauded the bipartisan support for the PACT Act at the signing.
“There are a lot of issues we can...
Source: Asbestos and Mesothelioma News - August 10, 2022 Category: Environmental Health Authors: Chris Elkins Tags: Veterans Source Type: news
New Options in Myelodysplastic Syndromes From ASCO 2022 New Options in Myelodysplastic Syndromes From ASCO 2022
Novel treatment options in lower- and higher-risk patients with myelodysplastic syndromes and a promising targeted therapy are among MDS highlights from ASCO 2022, as discussed by Dr Amy DeZern.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
